Cooper Companies COO
- Market cap
- $11.6B
- PE
- 20.9×
- 10y median 40.2×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.7×
- EV/EBIT
- 17.2×
- Revenue, 12 months
- $4.2B
- +5% on a year ago
- Net margin
- 13.5%
- Free cash flow yield
- 5.8%
Cooper Companies trades at 20.9× trailing earnings, cheaper than 94% of the last ten years. Revenue was $4.2B over the last twelve months, up 5% on a year earlier with a 13% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $927.1M+9% | $931.6M+9% | $942.6M+7% | $1B+8% | $1B+10% | $964.7M+4% | $1B+6% | $1.1B+6% | $1.1B+5% | $1B+6% | $1.1B+8% | $1.1B+1% | |
| Cost of revenue | $320.6M+3% | $307.8M+3% | $311.4M+6% | $339.8M+6% | $340.7M+6% | $304.5M−1% | $323.2M+4% | $368.3M+8% | $414.3M+22% | $328.9M+8% | $346.1M+7% | $354.3M−4% |
| Gross profit | $606.5M+13% | $623.8M+12% | $631.2M+8% | $663M+9% | $677.7M+12% | $660.2M+6% | $679.1M+8% | $692M+4% | $650.8M−4% | $695.2M+5% | $735.4M+8% | $711.9M+3% |
| R&D | $36.7M+26% | $39.5M+25% | $38.9M+19% | $39M+7% | $37.7M+3% | $40.7M+3% | $45.5M+17% | $44.6M+14% | $41.4M+10% | $44.3M+9% | $42.5M−7% | $41.6M−7% |
| SG&A | $387.6M+8% | $380.9M+15% | $380.3M−7% | $381.1M+2% | $391.4M+1% | $387.9M+2% | $399M+5% | $421.7M+11% | $419.2M+7% | $390.2M+1% | $676.2M+70% | $401.3M−5% |
| $135.7M+31% | $153.1M+2% | $161.7M+68% | $192.5M+27% | $198.4M+46% | $182M+19% | $184.8M+14% | $175.7M−9% | $140.4M−29% | $212.8M+17% | −$31M | $222M+26% | |
| Interest expense | $26.3M+15% | $29.9M+15% | $28.9M+11% | $28.5M+6% | $27M+3% | $26M−13% | $24.2M−16% | $25.4M−11% | $24.4M−10% | $22.4M−14% | $20.9M−14% | $21.5M−15% |
| Pre-tax income | $106.4M+47% | $120M−2% | $130M+98% | $163.7M+38% | $168.6M+59% | $153.3M+28% | $144.5M+11% | $151.9M−7% | $116.8M−31% | $192.2M+25% | −$48.4M | $201.8M+33% |
| $21.9M+222% | $38.8M+4% | $41.1M+59% | $59M+76% | $51.1M+133% | $49M+26% | $56.8M+38% | $53.6M−9% | $32.2M−37% | $61.4M+25% | $29.5M−48% | −$231M | |
| Net income | $84.5M+29% | $81.2M−4% | $88.9M+123% | $104.7M+23% | $117.5M+39% | $104.3M+28% | $87.7M−1% | $98.3M−6% | $84.6M−28% | $130.8M+25% | −$77.9M | $432.8M+340% |
| $0.42+27% | $0.41−5% | $0.44+120% | $0.52+21% | $0.59+41% | $0.52+27% | $0.44+0% | $0.49−6% | $0.43−27% | $0.66+27% | −$0.40 | $2.24+357% | |
| 199.6M+0% | 199.9M+1% | 200.5M+1% | 200.6M+1% | 200.7M+1% | 201.2M+1% | 200.7M+0% | 200M−0% | 198.2M−1% | 196.7M−2% | 195M−3% | 193.4M−3% |
EPS, diluted: 9 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 17 periods, Q4 FY09 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Cooper Companies' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| COOCooper Companies | $11.6B | 20.9× | 40.2× | n/m | 2.7× | +5% | 13.5% |
| ALGNAlign Technology | $11B | 26.9× | 43.3× | n/m | 2.7× | +4% | 10.0% |
| GMEDGlobus Medical | $10.9B | 20.8× | 37.4× | n/m | 3.5× | +20% | 17.0% |
| PENPenumbra | $12.8B | 79.7× | 197× | n/m | 8.5× | +18% | 10.7% |
| PODDInsulet | $10.3B | 27.9× | 63.0× | n/m | 3.4× | +29% | 12.3% |
| SOLVSolventum | $14.5B | 10.4× | 10.7× | n/m | 1.7× | −1% | 17.3% |
| MSAMSA Safety | $7B | 22.7× | 36.3× | n/m | 3.6× | +6% | 16.1% |
| MMSIMerit Medical Systems | $5.6B | 38.6× | 57.5× | n/m | 3.5× | +10% | 9.2% |
| HAEHaemonetics | $5.4B | 58.1× | 51.6× | n/m | 4.0× | +0% | 7.1% |
| WSTWest Pharmaceutical Services | $27.6B | 50.2× | 45.8× | 42.2× | 8.3× | +12% | 17.0% |
| VNTVontier | $4.6B | 14.3× | 13.5× | n/m | 1.5× | +1% | 11.3% |
| Peer median | $10.6B | 27.4× | 44.6× | 42.2× | 3.5× | +8% | 11.8% |
Investors who own it
Investors we follow who held Cooper Companies at the end of Jun 30, 2026, from their 13F filings.
- Bill NygrenHarris Associates (Oakmark)0.1% of portfolionew
- Ron BaronBaron Capital0.0% of portfoliotrimmed
More on Cooper Companies
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #1of 23Medical instruments and supplies stocks cheapest against their own PE history
- #8of 92Healthcare stocks cheapest against their own PE history
- #10of 33Medical instruments and supplies stocks with the fastest earnings growth
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .